LDLR and familial hypercholesterolemia: Recent advancements in gene therapy for the treatment of hypercholesterolemia focused on the codon optimization of the AAV vector have shown encouraging results in LDLR−/−/apobec1−/− double knockout mice [207,208] (Table 2).